Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NYSE:ANVS NASDAQ:ERNA NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$2.29-6.5%$2.51$1.78▼$8.56$47.84M0.77111,509 shs129,902 shsANVSAnnovis Bio$2.56-1.6%$2.68$1.11▼$10.54$49.69M1.51287,986 shs163,521 shsERNAErnexa Therapeutics$1.70+3.2%$2.11$1.50▼$29.25$12.52M5.4288,236 shs13,614 shsPDSBPDS Biotechnology$1.11-0.9%$1.36$0.85▼$4.29$50.74M0.95420,059 shs248,191 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%-1.29%-15.81%-18.21%-66.07%ANVSAnnovis Bio0.00%+1.95%-11.15%+66.71%-68.09%ERNAErnexa Therapeutics0.00%+8.97%-14.14%-42.73%-93.38%PDSBPDS Biotechnology0.00%+1.83%-14.62%-6.82%-63.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.0444 of 5 stars3.44.00.04.80.61.70.6ANVSAnnovis Bio1.4367 of 5 stars3.51.00.00.00.01.70.6ERNAErnexa Therapeutics0.6519 of 5 stars0.05.00.00.00.61.70.0PDSBPDS Biotechnology1.47 of 5 stars3.73.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.80Moderate Buy$23.80939.30% UpsideANVSAnnovis Bio 3.00Buy$18.00603.40% UpsideERNAErnexa Therapeutics 0.00N/AN/AN/APDSBPDS Biotechnology 3.33Buy$9.00710.81% UpsideCurrent Analyst Ratings BreakdownLatest ERNA, PDSB, ANVS, and ADVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/26/2025ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.005/15/2025ADVMAdverum BiotechnologiesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.005/15/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.005/15/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.00(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M47.84N/AN/A$3.40 per share0.67ANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AERNAErnexa Therapeutics$580K21.57N/AN/A$0.50 per share3.40PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)ERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-285.71%8/12/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/13/2025 (Estimated)Latest ERNA, PDSB, ANVS, and ADVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ANVSAnnovis Bio-$0.36N/AN/AN/AN/AN/A8/13/2025Q2 2025PDSBPDS Biotechnology-$0.24N/AN/AN/AN/AN/A8/11/2025Q2 2025ADVMAdverum Biotechnologies-$2.24N/AN/AN/AN/AN/A5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A3.573.57ANVSAnnovis BioN/A10.6810.68ERNAErnexa TherapeuticsN/A0.210.21PDSBPDS Biotechnology0.292.332.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ANVSAnnovis Bio15.83%ERNAErnexa Therapeutics70.55%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%ANVSAnnovis Bio20.80%ERNAErnexa Therapeutics1.50%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.89 million19.64 millionOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableERNAErnexa Therapeutics107.36 million7.26 millionNo DataPDSBPDS Biotechnology2045.71 million41.51 millionOptionableERNA, PDSB, ANVS, and ADVM HeadlinesRecent News About These CompaniesPDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comPDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comPDS Biotechnology (NASDAQ:PDSB) Trading 8.7% Higher - What's Next?July 24, 2025 | marketbeat.comPDS wasn’t a bad deal, few greedy individuals cannibalised it with self-serving interests – John JinaporJuly 16, 2025 | modernghana.comMPDS deal was not bad but greedy people decided to cannibalise the process - JinaporJuly 16, 2025 | ghanaweb.comGEnergy Minister blames ‘greedy individuals’ for undermining ‘otherwise good’ PDS dealJuly 16, 2025 | myjoyonline.comMPDS to pay final dividend of ₹1.70, ex-date due tomorrow; last day today to trade sharesJuly 16, 2025 | moneycontrol.comThe top headlines for PDS Health’s busy 2025 so farJuly 12, 2025 | beckersdental.comBPDS Biotechnology stock rises after trial meets criteria for expansionJuly 10, 2025 | investing.comPDS Biotechnology Shares Climb Following Trial Expansion MilestoneJuly 10, 2025 | msn.comPDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 ResultsJuly 10, 2025 | globenewswire.comASIC consults on simplifying PDS guidanceJuly 10, 2025 | professionalplanner.com.auPAP: over 11k kg of PDS rice seized in a private premiseJuly 10, 2025 | uniindia.comUOne arrested for smuggling PDS rice near TiruchiJuly 7, 2025 | thehindu.comPDS Health adds practices in 5 statesJuly 3, 2025 | beckersdental.comB3 booked for illegally transporting PDS food grains stock for sale in ThaneJuly 3, 2025 | theprint.inTPDS arm inks pact to acquire 60% stake in GSC LinkJuly 3, 2025 | business-standard.comBTwo errant traders arrested; 79.3 quintals of PDS rice seizedJune 25, 2025 | thehindu.comPDS Health Raises Over $1.9 Million Through Smile Generation to Support charity: water's Clean Water ProjectsJune 25, 2025 | kxan.comKPDS Biotechnology Corporation (PDSB) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPDS Health ranked among most community-minded companiesJune 13, 2025 | beckersdental.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermBy Leo Miller | July 22, 2025View Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermCSX Stock Rally: Strong Options Flow, Analyst Price TargetsBy Jeffrey Neal Johnson | July 18, 2025View CSX Stock Rally: Strong Options Flow, Analyst Price TargetsGlobal Value: 3 Stocks Under $10 Riding a Weak DollarBy Chris Markoch | July 30, 2025View Global Value: 3 Stocks Under $10 Riding a Weak Dollar3 Retailers Poised to Outmaneuver Tariff and Recession ConcernsBy Nathan Reiff | July 20, 2025View 3 Retailers Poised to Outmaneuver Tariff and Recession ConcernsPower Solutions International Poised for 75% UpsideBy Thomas Hughes | July 12, 2025View Power Solutions International Poised for 75% UpsideERNA, PDSB, ANVS, and ADVM Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$2.29 -0.16 (-6.53%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.30 +0.01 (+0.44%) As of 08/8/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Annovis Bio NYSE:ANVS$2.56 -0.04 (-1.58%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$2.58 +0.02 (+0.82%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Ernexa Therapeutics NASDAQ:ERNA$1.70 +0.05 (+3.19%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$1.68 -0.01 (-0.88%) As of 08/8/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.PDS Biotechnology NASDAQ:PDSB$1.11 -0.01 (-0.89%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.11 0.00 (0.00%) As of 08/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
